Huntington's disease therapeutic compounds
US9523093B2 · kind B2 · utility
15Cited by
19References
53Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 20, 2015 |
| Grant date | Dec 20, 2016 |
| Priority date | — |
| Expiry date | May 20, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2330/51
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to RNA interference (RNAi) molecules targeted against a Huntington's disease nucleic acid sequence, and methods of using these RNAi molecules to treat Huntington's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.